{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:12:39Z","timestamp":1770293559016,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Open Access funding enabled and organized by Projekt DEAL."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Secondary sclerosing cholangitis in critically ill patients (SC-CIP) is a rare disease characterized by chronic cholestasis. The underlying pathophysiology of SC-CIP is not fully understood, and prognosis in severe cases remains poor with liver transplantation remaining the only curative treatment option. There is a growing amount of literature describing patients with chronic cholangiopathy after COVID-19 infection. The vast majority of the patients described in these reports were male and had a poor outcome. While the exact percentage of patients with COVID-19-related SC-CIP cannot be estimated accurately due to a lack of larger studies, an increase in patients with long-term complications of chronic cholestatic liver disease after severe COVID19-pneumonia can be expected in the upcoming years. Treatment options remain limited and further research is needed to improve the dismal prognosis of SC-CIP. Here, we present the cases of two patients who developed SC-CIP after prolonged intensive care unit stay due to severe COVID-19 pneumonia. Both patients required invasive ventilation for 31 and 141\u00a0days, respectively, as well as extra-corporal membrane\u00a0oxygenation for 23 and 87\u00a0days. The patients suffered from jaundice and severe pruritus, and typical features of SC-CIP were present by MRCP and ERC. Repeated removal of biliary casts resulted in some alleviation of their clinical symptoms, but cholestasis parameters remain elevated. Furthermore, an increased liver stiffness was indicative of advanced fibrosis in both patients. In addition to these two case reports, we provide a concise review of the literature of SC-CIP after COVID-19 infection and discuss risk factors, treatment options and prognosis.<\/jats:p>","DOI":"10.1007\/s12328-022-01687-5","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T16:49:39Z","timestamp":1660236579000},"page":"1124-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Secondary sclerosing cholangitis after COVID-19 pneumonia: a report of two cases and review of the literature"],"prefix":"10.1007","volume":"15","author":[{"given":"Ulrike","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desislava","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Lahmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland M.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-1953","authenticated-orcid":false,"given":"Ursula","family":"Ehmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"1687_CR1","first-page":"929","volume":"35","author":"M Schmitt","year":"1997","unstructured":"Schmitt M, Kolbel CB, Muller MK, et al. Sclerosing cholangitis after burn injury. Z Gastroenterol. 1997;35:929\u201334.","journal-title":"Z Gastroenterol"},{"key":"1687_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrgastro.2009.46","volume":"6","author":"P Ruemmele","year":"2009","unstructured":"Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol. 2009;6:287\u201395.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1687_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002188","volume":"94","author":"S Leonhardt","year":"2015","unstructured":"Leonhardt S, Veltzke-Schlieker W, Adler A, et al. Secondary sclerosing cholangitis in critically ill patients: clinical presentation, cholangiographic features, natural history, and outcome: a series of 16 cases. Medicine. 2015;94: e2188.","journal-title":"Medicine"},{"key":"1687_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1055\/s-0032-1325733","volume":"44","author":"T Voigtlander","year":"2012","unstructured":"Voigtlander T, Negm AA, Schneider AS, et al. Secondary sclerosing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome. Endoscopy. 2012;44:1055\u20138.","journal-title":"Endoscopy"},{"key":"1687_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/lt.24192","volume":"21","author":"T Voigtlander","year":"2015","unstructured":"Voigtlander T, Jaeckel E, Lehner F, et al. Liver transplantation for critically Ill patients with secondary sclerosing cholangitis: outcome and complications. Liver Transpl. 2015;21:1295\u20139.","journal-title":"Liver Transpl"},{"key":"1687_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CEG.S115518","volume":"10","author":"HO Gudnason","year":"2017","unstructured":"Gudnason HO, Bjornsson ES. Secondary sclerosing cholangitis in critically ill patients: current perspectives. Clin Exp Gastroenterol. 2017;10:105\u201311.","journal-title":"Clin Exp Gastroenterol"},{"key":"1687_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000501405","volume":"27","author":"P Martins","year":"2020","unstructured":"Martins P, Verdelho MM. Secondary sclerosing cholangitis in critically ill patients: an underdiagnosed entity. GE Port J Gastroenterol. 2020;27:103\u201314.","journal-title":"GE Port J Gastroenterol"},{"key":"1687_CR8","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"1687_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497\u2013506.","journal-title":"China Lancet"},{"key":"1687_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41575-021-00426-4","volume":"18","author":"T Marjot","year":"2021","unstructured":"Marjot T, Webb GJ, Barritt AS, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18:348\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"1687_CR11","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1111\/liv.14971","volume":"41","author":"S Butikofer","year":"2021","unstructured":"Butikofer S, Lenggenhager D, Wendel Garcia PD, et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int. 2021;41(10):2404-17.","journal-title":"Liver Int"},{"key":"1687_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00134-021-06445-8","volume":"47","author":"P Meersseman","year":"2021","unstructured":"Meersseman P, Blondeel J, De Vlieger G, et al. Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients. Intensive Care Med. 2021;47:1037\u201340.","journal-title":"Intensive Care Med"},{"key":"1687_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.14309\/ajg.0000000000001264","volume":"116","author":"S Faruqui","year":"2021","unstructured":"Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy after severe COVID-19: clinical features and prognostic implications. Am J Gastroenterol. 2021;116:1414\u201325.","journal-title":"Am J Gastroenterol"},{"key":"1687_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jhep.2021.02.007","volume":"74","author":"V Mallet","year":"2021","unstructured":"Mallet V, Keta-Cov research group. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021;74:1243\u20134.","journal-title":"J Hepatol"},{"key":"1687_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/hep.31650","volume":"74","author":"SAI Knooihuizen","year":"2021","unstructured":"Knooihuizen SAI, Aday A, Lee WM. Ketamine-induced sclerosing cholangitis (KISC) in a critically ill patient with COVID-19. Hepatology. 2021;74:519\u201321.","journal-title":"Hepatology"},{"key":"1687_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ajg.2010.485","volume":"106","author":"WK Seto","year":"2011","unstructured":"Seto WK, Ng M, Chan P, et al. Ketamine-induced cholangiopathy: a case report. Am J Gastroenterol. 2011;106:1004\u20135.","journal-title":"Am J Gastroenterol"},{"key":"1687_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/hep.26459","volume":"58","author":"A Turkish","year":"2013","unstructured":"Turkish A, Luo JJ, Lefkowitch JH. Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis. Hepatology. 2013;58:825\u20137.","journal-title":"Hepatology"},{"key":"1687_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/cs0820169","volume":"82","author":"A Thune","year":"1992","unstructured":"Thune A, Jivegard L, Pollard H, et al. Location of enkephalinase and functional effects of [Leu5]enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin Sci. 1992;82:169\u201373.","journal-title":"Clin Sci"},{"key":"1687_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100116","volume":"4","author":"M Rojas","year":"2021","unstructured":"Rojas M, Rodriguez Y, Zapata E, et al. Cholangiopathy as part of post-COVID syndrome. J Transl Autoimmun. 2021;4: 100116.","journal-title":"J Transl Autoimmun"},{"key":"1687_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.14309\/ajg.0000000000001154","volume":"116","author":"NC Roth","year":"2021","unstructured":"Roth NC, Kim A, Vitkovski T, et al. Post-COVID-19 cholangiopathy: a novel entity. Am J Gastroenterol. 2021;116:1077\u201382.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1687_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cld.667","volume":"10","author":"J Lewis","year":"2017","unstructured":"Lewis J. Pathological patterns of biliary disease. Clin Liver Dis. 2017;10(5):107\u201310.","journal-title":"Clin Liver Dis"},{"key":"1687_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.5858\/arpa.2014-0229-RA","volume":"139","author":"Y Nakanishi","year":"2015","unstructured":"Nakanishi Y, Saxena R. Pathophysiology and diseases of the proximal pathways of the biliary system. Arch Pathol Lab Med. 2015;139:858\u201366.","journal-title":"Arch Pathol Lab Med"},{"key":"1687_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/HMER.S205431","volume":"12","author":"MT Aguilar","year":"2020","unstructured":"Aguilar MT, Chascsa DM. Update on emerging treatment options for primary biliary cholangitis. Hepat Med. 2020;12:69\u201377.","journal-title":"Hepat Med"},{"key":"1687_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/gut.52.5.688","volume":"52","author":"S Engler","year":"2003","unstructured":"Engler S, Elsing C, Flechtenmacher C, et al. Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders. Gut. 2003;52:688\u201393.","journal-title":"Gut"},{"key":"1687_CR25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.transproceed.2021.03.007","volume":"53","author":"FA Durazo","year":"2021","unstructured":"Durazo FA, Nicholas AA, Mahaffey JJ, et al. Post-Covid-19 cholangiopathy-A new indication for liver transplantation: a case report. Transplant Proc. 2021;53:1132\u20137.","journal-title":"Transplant Proc"},{"issue":"5","key":"1687_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4068","volume":"9","author":"C Klindt","year":"2021","unstructured":"Klindt C, Jensen BE, Brandenburger T, et al. Secondary sclerosing cholangitis as a complication of severe COVID-19: a case report and review of the literature. Clin Case Rep. 2021;9(5): e04068.","journal-title":"Clin Case Rep"},{"issue":"8","key":"1687_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244168","volume":"14","author":"A Lee","year":"2021","unstructured":"Lee A, Wein AN, Doyle MBM, et al. Liver transplantation for post-COVID-19 sclerosing cholangitis. BMJ Case Rep. 2021;14(8): e244168.","journal-title":"BMJ Case Rep"},{"key":"1687_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.clinimag.2021.07.017","volume":"80","author":"S Tafreshi","year":"2021","unstructured":"Tafreshi S, Whiteside I, Levine I, et al. A case of secondary sclerosing cholangitis due to COVID-19. Clin Imaging. 2021;80:239\u201342.","journal-title":"Clin Imaging"},{"key":"1687_CR29","volume":"13","author":"D Sanders","year":"2021","unstructured":"Sanders D, Bomman S, Irani S. COVID-19-induced bile duct casts and cholangitis: a case report. Cureus. 2021;13: e14560.","journal-title":"Cureus"},{"issue":"11","key":"1687_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237984","volume":"13","author":"K Edwards","year":"2020","unstructured":"Edwards K, Allison M, Ghuman S. Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep. 2020;13(11): e237984.","journal-title":"BMJ Case Rep"},{"issue":"12","key":"1687_CR31","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1055\/a-1647-3785","volume":"59","author":"B Arnstadt","year":"2021","unstructured":"Arnstadt B, Zillinger C, Treitl M, et al. Corona again? SSC after a severe COVID-disease. Z Gastroenterol. 2021;59(12):1304\u20138.","journal-title":"Z Gastroenterol"},{"issue":"12","key":"1687_CR32","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/biomedicines9121841","volume":"9","author":"D Tampe","year":"2021","unstructured":"Tampe D, Korsten P, Bremer SCB, et al. Kinetics of bilirubin and ammonia elimination during hemadsorption therapy in secondary sclerosing cholangitis following ECMO therapy and severe COVID-19. Biomedicines. 2021;9(12):1841.","journal-title":"Biomedicines."}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01687-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T14:37:22Z","timestamp":1700923042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01687-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01687-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (University Hospital rechts der Isar, 178\/20S) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}